Kevin Sayer Joins Guardant Health Board of Directors
Key Highlights
- ➤Kevin Sayer appointed to Guardant Health (GH) board of directors
- ➤Former Dexcom CEO brings digital health technology leadership experience
- ➤Sayer served as Dexcom CEO from 2015 to 2026
- ➤Guardant highlights liquid biopsy, AI, and personalized cancer care strategy
Expert Statements
Helmy Eltoukhy, Chairman and co-CEO of Guardant Health
“We are excited to welcome Kevin Sayer to Guardant’s board,”
Helmy Eltoukhy, Chairman and co-CEO of Guardant Health
“Kevin has played a pivotal role in advancing innovations that have transformed how people monitor and manage disease and has a strategic and operations record delivering significant growth. His expertise will be invaluable to Guardant as we continue to pioneer innovations in how we screen, monitor, and treat disease.”
Kevin Sayer, Executive Chairman of the Dexcom board and Guardant Health board member
“Guardant’s leadership in liquid biopsy puts it in a powerful position to shape the next era of cancer care and disease detection, where AI can turn increasingly rich molecular data into more precise, actionable insights,”
Kevin Sayer, Executive Chairman of the Dexcom board and Guardant Health board member
“I’m excited to work with the team to build on that leadership and help bring the benefits of earlier detection and more personalized treatment to more patients.”
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the appointment of Kevin Sayer to its board of directors. Mr. Sayer is former CEO of Dexcom, Inc. and current Executive Chairman of the Dexcom board, with decades of strategic leadership experience in digital health technology.
“We are excited to welcome Kevin Sayer to Guardant’s board,” said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. “Kevin has played a pivotal role in advancing innovations that have transformed how people monitor and manage disease and has a strategic and operations record delivering significant growth. His expertise will be invaluable to Guardant as we continue to pioneer innovations in how we screen, monitor, and treat disease.”
Get started
Create a free account to read the full story.